Suppr超能文献

预后生物标志物与急性肾损伤:提高识别术后肾功能丧失风险患者的潜力

Prognostic Biomarkers and AKI: Potential to Enhance the Identification of Post-Operative Patients at Risk of Loss of Renal Function.

作者信息

Singh Rishabh, Watchorn James C, Zarbock Alexander, Forni Lui G

机构信息

Department of Surgery, Royal Surrey Hospital, Guildford, Surrey, UK.

Intensive Care Unit, Royal Berkshire NHS Foundation Trust, Reading, Berkshire, UK.

出版信息

Res Rep Urol. 2024 Mar 5;16:65-78. doi: 10.2147/RRU.S385856. eCollection 2024.

Abstract

Acute kidney injury (AKI) is a common complication after surgery and the more complex the surgery, the greater the risk. During surgery, patients are exposed to a combination of factors all of which are associated with the development of AKI. These include hypotension and hypovolaemia, sepsis, systemic inflammation, the use of nephrotoxic agents, tissue injury, the infusion of blood or blood products, ischaemia, oxidative stress and reperfusion injury. Given the risks of AKI, it would seem logical to conclude that early identification of patients at risk of AKI would translate into benefit. The conventional markers of AKI, namely serum creatinine and urine output are the mainstay of defining chronic kidney disease but are less suited to the acute phase. Such concerns are compounded in surgical patients given they often have significantly reduced mobility, suboptimal levels of nutrition and reduced muscle bulk. Many patients may also have misleadingly low serum creatinine and high urine output due to aggressive fluid resuscitation, particularly in intensive care units. Over the last two decades, considerable information has accrued with regard to the performance of what was termed "novel" biomarkers of AKI, and here, we discuss the most examined molecules and performance in surgical settings. We also discuss the application of biomarkers to guide patients' postoperative care.

摘要

急性肾损伤(AKI)是手术后常见的并发症,手术越复杂,风险越大。手术期间,患者会受到多种因素的综合影响,所有这些因素都与AKI的发生有关。这些因素包括低血压和低血容量、脓毒症、全身炎症、使用肾毒性药物、组织损伤、输注血液或血液制品、缺血、氧化应激和再灌注损伤。鉴于AKI的风险,似乎可以合理地得出结论,早期识别有AKI风险的患者会带来益处。AKI的传统标志物,即血清肌酐和尿量,是定义慢性肾脏病的主要依据,但不太适用于急性期。对于外科患者来说,这些问题更加复杂,因为他们通常活动能力显著下降、营养水平欠佳且肌肉量减少。由于积极的液体复苏,许多患者的血清肌酐可能会误导性地偏低,尿量可能会偏高,尤其是在重症监护病房。在过去二十年中,关于所谓AKI“新型”生物标志物的性能已经积累了大量信息,在此,我们讨论在外科环境中研究最多的分子及其性能。我们还讨论生物标志物在指导患者术后护理方面的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24d/10928916/2e1213369214/RRU-16-65-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验